Coronavirus company news summary – Moderna signs another manufacturing agreement – Leading vaccine developers to testify to US subcommittee about progress

Allie Nawrat 10 July 2020 (Last Updated July 10th, 2020 09:13)

10 July 2020

Moderna has partnered with European pharmaceutical company Laboratorios Farmacéuticos Rovi for finish-fill manufacturing of its Covid-19 vaccine candidate, mRNA-1273. As part of the deal, Rovi will be responsible for large-scale, commercial fill-finish manufacturing of the vaccine product at its facility in Madrid, Spain. This is expected to support manufacturing of millions of doses of mRNA-1273 to supply primarily in markets outside of the US.

Altimmune has signed an agreement with DynPort Vaccine to support US Government funding efforts for the development of its intranasal Covid-19 vaccine candidate, AdCOVID. If successful, the partnership will be extended to programme management, drug development and regulatory support for the vaccine candidate.

Officials from AstraZeneca, Pfizer, Merck, Johnson & Johnson and Moderna are set to testify at a remote hearing to be held on 21 July by the US Energy and Commerce Oversight and Investigations Subcommittee regarding progress on their Covid-19 vaccine development efforts. The officials will also discuss their ongoing preparations for manufacturing and distribution.

African Union Commission has introduced the new Africa Centres for Disease Control and Prevention (Africa CDC) Consortium for COVID-19 Vaccine Clinical Trial (CONCVACT) to ensure access to a safe vaccine against the disease in Africa. CONCVACT intends to secure more than ten late-stage vaccine trials at the earliest. This announcement comes a day after the US National Institutes of Health (NIH) launched a new clinical trials network for testing potential vaccines and monoclonal antibodies against Covid-19.